Sign In
Buy KROS
$11.15
+0.500 (+4.69%)
At Close: Aug 07, 2026
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?
12:41pm, Monday, 20'th Apr 2026
Keros Therapeutics KROS reshaped its financial profile in 2025 by pairing a major licensing transaction with a shift in development responsibilities. The result was a step-change in reported revenue
KROS Rinvatercept: What to Know Before DMD Phase II Starts
12:30pm, Monday, 20'th Apr 2026
KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward execution and high-stakes clinical catalysts.
JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS
04:45am, Monday, 06'th Apr 2026
JPMorgan Chase and Co. grew its position in shares of Keros Therapeutics, Inc. (NASDAQ: KROS) by 260.8% during the third quarter, according to the company in its most recent disclosure with the Securi
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?
12:31pm, Friday, 03'rd Apr 2026
Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?
KROS Stock: What to Know About Rinvatercept in DMD
02:20pm, Tuesday, 17'th Mar 2026
Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 phase II start driving its near-term execution story.
KROS: Is the Discount Book Value a Value Trap?
02:20pm, Tuesday, 17'th Mar 2026
Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
02:20pm, Tuesday, 17'th Mar 2026
Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of “Hold” from Analysts
02:50am, Friday, 13'th Mar 2026
Keros Therapeutics, Inc. (NASDAQ: KROS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten analysts that are presently covering the company, Marketbeat reports. One
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
08:00am, Monday, 09'th Mar 2026
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and co
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and co
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
01:01pm, Friday, 06'th Mar 2026
KROS advances rinvatercept for Duchenne muscular dystrophy, with a phase II trial planned for 2026 after gaining FDA orphan drug designation.
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
06:10pm, Wednesday, 04'th Mar 2026
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $1.14 per share a year ago.
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
04:01pm, Wednesday, 04'th Mar 2026
LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and co
Keros Therapeutics Appoints Charles Newton to its Board of Directors
04:01pm, Thursday, 26'th Feb 2026
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
04:01pm, Wednesday, 18'th Feb 2026
LEXINGTON, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
